Revive Therapeutics Ltd. · CSE:RVV
Revive Therapeutics — Investor Presentation (February 2020)
23 slides from Revive Therapeutics's investor presentation, February 2020
Slide 1: Cannabis and Psychedelic Life Sciences Company
Cannabis and Psychedelic Life Sciences Company Corporate Presentation February 2020 Revive Therapeutics Ltd. | Office: 905-605-5535 | E-mail: [email protected]
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future f
Slide 3: Revive Therapeutics
REVIVE THERAPEUTICS § Emerging cannabis and psychedelic life sciences company § Developing novel cannabis and psychedelic based therapies to treat liver, inflammatory, and rare diseases § Robust cannabis and psychedelic based product portfolio targeting multi-billion market opportunities § Significa
Slide 4: Pharma Cannabis Market Opportunity
PHARMA CANNABIS MARKET OPPORTUNITY
Slide 5: Cannabinoid Pharmaceutical Strategy
CANNABINOID PHARMACEUTICAL STRATEGY Cannabinoids may Targeting Inflammation Novel Cannabinoid FDA Orphan Designations represent ~10% of $20 and Rare Diseases Delivery System Billion specialty pharma market over next 5 years1
Slide 6: Cannabinoid Delivery Technology
CANNABINOID DELIVERY TECHNOLOGY § Delivering naturally extracted and synthetic cannabinoids with novel combination of composites via multiple delivery formats • Tannin (plant-based) - antibacterial, antifungal, antioxidant & wound healing properties • Chitosan (shrimp-based) - blood-clotting & antim
Slide 7: Patent Portfolio
PATENT PORTFOLIO SCIENCE AND IP DRIVEN CANNABIS-BASED PRODUCTS 4 Exclusive licenses to patents Cannabinoid Patents Compelling Features Delivery System Improved bioavailability Liver disease Delivery options (oral, buccal, topical) Rapid, Sustained, Controlled delivery Improved safety, effectiveness,
Slide 8: Product Pipeline
PRODUCT PIPELINE CANNABINOID PHARMACEUTICALS Addressable Product Candidates Target Indications US Population Development Market Size Status Dermatitis, Psoriasis, Acne $25Bn +40mm Topical CBD Wound Care $35Bn Preclinical 12mm Liver diseases: Autoimmune Oral/IV CBD Hepatitis, Nonalcoholic $19.5Bn 30m
Slide 9: Liver Disease Opportunity
LIVER DISEASE OPPORTUNITY § Potential $19.5Bn market by 2022; affecting +30mm people in U.S. § Focus on Autoimmune Hepatitis (AIH) and Nonalcoholic steatohepatitis (NASH) § AIH - rare disease (~ 76k patients in US) causing liver inflammation • Drawbacks of current therapies (steroids): Severe side e
Slide 10: Inflammatory Skin Disease Opportunity
INFLAMMATORY SKIN DISEASE OPPORTUNITY § Inflammatory skin diseases from immune system reactions Psoriasis § Unmet medical need requiring new treatment options • Current treatments are inadequate, have unwanted side effects profiles, and expensive Dermatitis § Dermatitis (Eczema) Market Opportunity •
Slide 11: Wound Care Opportunity
WOUND CARE OPPORTUNITY § Global wound care market estimated at USD $35Bn by 2022 Diabetic Foot Ulcer § Unmet medical need requiring new treatment options § Types of wounds include surgical scars, burns and diabetic foot and pressure ulcers § Diabetic Foot and and Pressure Ulcers Opportunity Surgical
Slide 12: Psychedelic Opportunity
PSYCHEDELIC OPPORTUNITY § Entered into LOI to acquire Psilocin Pharma Corp. (PPC) § PPC has novel methods of production of Psilocybin-based formulations § Developed six unique formulations for both natural and synthetically derived Psilocybin § Capsules (PSY-0.1), Sublingual Spray (PSY-0.2), Gel Cap
Slide 13: Founder – Psilocin Pharma
FOUNDER – PSILOCIN PHARMA § Derrick Welsh § 14 years of Health Care experience, with the past 5 years in the Cannabis industry § Worked with several high profile publicly-traded Cannabis companies like Xanthic Bio Pharma and Green Growth Brands § Developed several patent pending formulations such as
Slide 14: Psilocybin Capsules (PSY-0.1)
PSILOCYBIN CAPSULES (PSY-0.1) Product highlights • Often easier to swallow • Protects sensitive ingredients • Easily opened • Reduced stomach irritation • Unique ingredient combinations are possible Micro Dosing involves taking roughly one-tenth • Gelatin and vegetarian enclosure options of a psyche
Slide 15: Psilocybin Sublingual Spray (PSY-0.2)
PSILOCYBIN SUBLINGUAL SPRAY (PSY-0.2) Product Highlights: • Faster onset and longer duration of action • Provides ease of administration to patients who refuse to swallow a tablet • There is no requirement of drug disintegration • Elimination of first pass metabolism, good mouth feels property • Low
Slide 16: Psilocybin Gel Cap (PSY-0.3)
PSILOCYBIN GEL CAP (PSY-0.3) Product Highlights • Often easier to swallow • Protects sensitive ingredients • Easily opened • Reduced stomach irritation • Unique ingredient combinations are possible • Gelatin and vegetarian enclosure options • Oil or fat-soluble nutrient delivery options Treatment Po
Slide 17: Psilocybin Effervescent Tablets (PSY-0.4/0.5)
PSILOCYBIN EFFERVESCENT TABLETS (PSY-0.4/0.5) Product Highlights • Increased uptake of Psilocin • Rapid metabolization via sublingual absorption path way • Easily dosed and titrated • Easily packaged and produced • Gentile on the gastrointestinal track • Marketing advantages Treatment Potential: • D
Slide 18: Psilocybin Oral Fast Dissolving Strip (PSY-0.6)
PSILOCYBIN ORAL FAST DISSOLVING STRIP (PSY-0.6) Product Highlights • Rapidly releases an expansive list of pharmaceuticals, emulsified psilocybin • Permits API’s to enter the blood stream through a fast dose pathway without being degraded or modified by first pass metabolism in the liver • Sublingua
Slide 19: Strategic Relationships
STRATEGIC RELATIONSHIPS Supply and collaboration LOI Acquisition Research collaboration of truffles Psychedelic pharma for liver diseases License of cannabidiol for License of cannabinoid Licensed Dealer of treatment of Autoimmune delivery technology medical cannabis Hepatitis (R&D, Testing)
Slide 20: Value Driving Milestones in 2020
VALUE DRIVING MILESTONES IN 2020 Q1-2020 Complete acquisition of Psilocin Pharma Corp. Q2-2020 Submit IND for Phase 1/2a clinical study for CBD in the treatment of Autoimmune Hepatitis Q2-2020 Pre-IND meeting with FDA for Psilocybin in treatment of mental illness (indication undisclosed) Q2/3-2020 I
Slide 21: Significantly Undervalued
SIGNIFICANTLY UNDERVALUED 3.9 B 105 M 90 M 60 M 5M
Slide 22: Team
TEAM Management Board of Directors § Michael Frank § Michael Frank Chairman and CEO Chairman and CEO § Carmelo Marrelli § William Jackson Chief Financial Officer Director § Joshua Herman Director § Christian Scovenna Director § Andrew Lindzon Director
Slide 23: Stock Information
STOCK INFORMATION Ticker Symbols RVV (CSE) Share Price CAD $0.075 (February 14, 2020) 52 week High/Low CAD $0.10 / $0.025 Capital Structure 72,411,282 common shares (90,466,657 fully-diluted) Market Cap CAD ~ $5,00,000
Revive Therapeutics — Investor Presentation (February 2020) on 6ix